CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 170 target
Drug / intervention
Keto Diet +1 morebehavioral
Likely dose
Not stated in record
Key inclusion· 6
  • Adults 18 years or older
  • Newly diagnosed glioblastoma within 2 months of initial diagnosis by histopathology
  • Not started standard of care chemotherapy and/or radiation therapy for glioblastoma
  • Karnofsky Performance Status (KPS) ≥ 70
Key exclusion· 10
  • Recurrent glioblastoma
  • Genetic disorders affecting lipid metabolism (pyruvate carboxylase deficiency, porphyria, primary carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine translocase deficiency, beta-oxidation defects)
  • Inability to wean steroids below 8mg dexamethasone per day or equivalent
  • Body Mass Index (BMI) < 21 kg/m² unless investigator deems safe

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05708352
NCT05708352Phase 2RecruitingHigh Momentum
Long Recruiting

A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients With Newly Diagnosed Glioblastoma in Combination With Standard-of-care Treatment

Cedars-Sinai Medical Center·interventional·Posted Feb 1, 2023·Updated May 6, 2026

In Brief

A Phase 2 clinical trial evaluating Keto Diet and Standard Anti-Cancer Diet for Glioblastoma Multiforme. Currently recruiting, targeting 170 participants across 5 sites.

Signals

Enrolling ahead of pace

Detailed Summary

This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-site study aims to provide evidence to support the hypothesis that a Keto Diet vs. Standard Anti-Cancer Diet improves overall survival in newly diagnosed glioblastoma multiforme patients who receive standard of care treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2Recruiting
2023202420252026202720282029
First PostedFeb 1, 2023
Enrollment StartJun 27, 2023
Primary CompletionSep 30, 2028
Study CompletionSep 30, 2029
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 3.4 years agoPrimary completion in 2.2 years

Interventions

Keto Dietbehavioral

The experimental intervention includes a strict and controlled diet that manages daily macronutrient breakdown and increases the ratio of dietary fat relative to protein and carbohydrate consumption.

Standard Anti-Cancer Dietbehavioral

Dietitian sessions will utilize the American Institute for Cancer Research Food resources and will reference foods low in fats such as fruits, vegetables and whole grains, providing key micronutrients and phytonutrients. Sessions will also focus on dietary support to help decrease any treatment related symptoms.